DEF: Predictive Oncology Faces Going Concern Warning

Predictive Oncology Inc. faces a "going concern" warning and seeks shareholder approval for significant equity issuance and an expanded incentive plan amidst substantial net losses and declining shareholder returns.

Summary

• Predictive Oncology Inc. will hold its Annual Meeting of Stockholders on November 25, 2025, to vote on five key proposals.
• Shareholders will elect two Class I directors, Daniel E. Handley and Chuck Nuzum, to serve until the 2028 Annual Meeting.
• The company seeks ratification of KPMG LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2025.
• A proposal to amend the 2024 Equity Incentive Plan will increase authorized shares from 66,667 to 1,066,667, plus shares from the 2012 Plan, and set a 500,000 share limit for incentive stock options.
• Approval is sought for the issuance of 14,903,393 shares of common stock upon the exercise of pre-funded warrants, as required by Nasdaq Listing Rule 5635(a).
• A non-binding advisory vote will be held to approve the compensation of the company's executive officers.
• The record date for the Annual Meeting is October 24, 2025, with 3,501,430 shares of common stock outstanding and entitled to vote.

Sentiment

Score: 2

Explanation: The filing reveals substantial doubt about the company's ability to continue as a going concern, material weaknesses in internal controls, and a dramatic decline in shareholder value over the past three years. While there are efforts to improve governance and strategic hires in digital assets, these are overshadowed by severe financial and operational challenges.

Positives

• The company has adopted sound corporate governance practices, including a Code of Ethics, a Recoupment of Incentive Compensation Policy (Clawback Policy) compliant with Nasdaq Rule 5608, and an Insider Trading Policy.
• The 2024 Equity Incentive Plan incorporates features like no evergreen provisions, no discounted stock options or SARs, prohibition on repricing without stockholder approval, and administration by an independent committee.
• Net loss decreased from $(25,737,634) in 2022 to $(12,664,388) in 2024, indicating some improvement in loss reduction.
• The appointment of Shawn Matthews, CEO of DNA Holdings Venture, Inc., to the Board and as chairperson of the new Cryptocurrency Subcommittee, along with Thomas L. McLaughlin as Chief Investment Officer with crypto expertise, suggests a strategic focus on digital asset management.

Negatives

• The company's independent auditor for 2023, BDO USA, P.C., issued a report containing an explanatory paragraph regarding "substantial doubt about the Company's ability to continue as a going concern."
• Material weaknesses in internal control over financial reporting were identified in 2023, specifically related to inadequate accounting resources for complex transactions and deficiencies in information technology general controls.
• The company reported significant net losses of $(12,664,388) in 2024, $(13,983,967) in 2023, and $(25,737,634) in 2022.
• Total Shareholder Return (TSR) has dramatically declined, with an initial $100 investment at the end of fiscal 2021 being worth only $4 by the end of 2024.
• No bonuses were paid to Named Executive Officers in fiscal years 2023 and 2024, and no stock option or stock appreciation right awards were granted to them in those years.
• The weighted average exercise price of outstanding stock options was $1,554.98 as of October 13, 2025, significantly higher than the market price of $13.47, indicating a large portion of existing options are underwater.
• The proposed amendment to the 2024 Equity Incentive Plan would increase the potential overhang from 1.5% to approximately 24%, indicating significant potential dilution for existing shareholders.
• If the proposal to approve the issuance of shares upon exercise of pre-funded warrants is not approved, the company is obligated to call a stockholders meeting every four months until approval is obtained, highlighting the critical nature of this capital raise.

Risks

• Substantial doubt exists about the Company's ability to continue as a going concern, as noted by the former independent auditor.
• Material weaknesses in internal control over financial reporting, including inadequate accounting resources for complex transactions and deficiencies in IT general controls, pose risks to financial reporting accuracy and reliability.
• Failure to approve the amendment to the 2024 Equity Incentive Plan could hinder the company's ability to attract, retain, and motivate employees, potentially leading to a competitive disadvantage and increased cash compensation expenses.
• The issuance of 14,903,393 shares of common stock upon exercise of pre-funded warrants, along with the proposed increase in the equity incentive plan, presents a significant risk of dilution to current shareholders.
• If stockholder approval for the pre-funded warrant issuance is not obtained, the company faces ongoing obligations to call stockholder meetings every four months, potentially incurring additional costs and uncertainty.

Future Outlook

The company anticipates that the proposed increase in the 2024 Equity Incentive Plan's share reserve will support equity-based awards at historical rates for approximately two to three years. It expects to require additional executive and operating officers, employees, and consultants to execute its business plans and drive future stockholder value, necessitating significant equity compensation. If the issuance of shares for pre-funded warrants is not approved, the company is committed to calling a stockholders meeting every four months until approval is secured. The Board will consider the outcome of the non-binding advisory vote on executive compensation when structuring future arrangements.

Management Comments

• "The Board of Directors believes that an increase in the aggregate number of shares authorized for issuance in connection with awards granted under the 2024 Plan is necessary to meet the Company’s anticipated equity compensation needs."
• "The Company currently has three executive officers and will require additional executive and operating officers, employees and consultants in order to effect its business plans that will drive future stockholder value. This factor, in turn, will require significant equity compensation in order to attract and motivate these new officers."
• "If the proposed Amendment to increase in the aggregate number of shares authorized for issuance in connection with options and awards granted under the 2024 Plan is not approved, the Company will lose a critical tool for recruiting, retaining and motivating employees. The Company would thus be at a competitive disadvantage in attracting and retaining talent."
• "The only way to make up this shortfall would be to increase the cash-based component of employee compensation, which would reduce the resources we are able to allocate to meet our business needs and objectives and could also reduce the future alignment of employee and stockholder interests."
• "We manage our long-term stockholder dilution by limiting what we grant to what we believe is an appropriate amount of equity necessary to attract, reward and retain employees."
• "We value stockholders opinions, and we will consider the outcome of that vote when determining future executive compensation arrangements."

Industry Context

Predictive Oncology Inc., primarily focused on oncology, is demonstrating an unusual strategic pivot or diversification by establishing a Cryptocurrency Subcommittee and appointing a Chief Investment Officer with expertise in liquid crypto markets. This suggests a potential integration of digital asset management into its treasury strategy or broader business model, which is not typical for a biotech company. The company's significant financial challenges, including a 'going concern' warning and internal control weaknesses, are particularly concerning in the capital-intensive biotechnology sector, where strong financial health and investor confidence are crucial for R&D and growth. The need for substantial equity compensation to attract talent is common in high-growth tech and biotech, but the scale of proposed dilution (24% overhang) and the poor historical TSR indicate a struggle to maintain competitive positioning and shareholder value.

Comparison to Industry Standards

• The 'substantial doubt about the Company's ability to continue as a going concern' and 'material weaknesses in internal control over financial reporting' are significantly below industry standards for publicly traded companies, indicating severe financial and operational deficiencies.
• A Total Shareholder Return (TSR) decline from $100 to $4 over three years is a stark underperformance compared to most industry peers and global benchmarks, reflecting a substantial loss of shareholder value.
• The proposed equity plan amendment, which would increase the overhang to approximately 24%, is on the higher end of dilution compared to industry averages, especially for a company facing financial distress and poor stock performance.
• The weighted average exercise price of outstanding stock options at $1,554.98, significantly above the market price of $13.47, suggests that a large portion of employee incentives are underwater, which is generally not seen in high-performing companies where equity acts as a strong retention and motivation tool.

Management Changes

Corporate Governance

Legal Proceedings

• Dr. Matthew J. Hawryluk's former employer, Gritstone bio, Inc., filed a voluntary petition for relief under Chapter 11 bankruptcy on October 10, 2024. Dr. Hawryluk resigned as an officer of Gritstone bio, Inc. effective December 31, 2024.

Related Party Transactions

• No related party transactions requiring disclosure have arisen or existed since the beginning of fiscal 2024, except as described in the proxy statement (which does not detail any specific transactions).

Stakeholder Impact

• **Shareholders:** Face significant potential dilution from the proposed equity incentive plan amendment (increasing overhang to 24%) and the issuance of 14,903,393 shares from pre-funded warrants. Historical Total Shareholder Return (TSR) has been extremely poor, and the company carries a 'going concern' warning, indicating high investment risk.
• **Employees/Management:** The proposed amendment to the 2024 Equity Incentive Plan is crucial for attracting, retaining, and motivating talent, particularly new executive and operating officers needed for business plans. Failure to approve could lead to competitive disadvantage and increased cash compensation.
• **Creditors:** The 'substantial doubt about the Company's ability to continue as a going concern' and material weaknesses in internal controls signal elevated credit risk.
• **Customers/Suppliers:** While not directly addressed, a company facing 'going concern' issues may experience challenges in maintaining operations, which could indirectly impact its ability to serve customers or pay suppliers.

Next Steps

• Hold the Annual Meeting of Stockholders on November 25, 2025, to vote on director elections, auditor ratification, equity plan amendment, pre-funded warrant share issuance, and executive compensation.
• If the Issuance Proposal for pre-funded warrants is not approved, the company will be obligated to call a stockholders meeting every four months until stockholder approval is obtained.
• Publish final voting results in a Current Report on Form 8-K within four business days after the Annual Meeting.
• Stockholder proposals for the 2026 Annual Meeting must be received between August 27, 2026, and September 25, 2026 (if the meeting is held between October 25, 2026, and January 22, 2027).

Key Dates

Recommendation

The filing presents critical red flags that warrant a 'strong sell' recommendation. The explicit 'substantial doubt about the Company's ability to continue as a going concern' from its former auditor, coupled with identified 'material weaknesses in internal control over financial reporting,' indicates severe financial instability and operational deficiencies. The dramatic decline in Total Shareholder Return (TSR) from $100 to $4 over three years demonstrates a profound loss of shareholder value. While the company is attempting to raise capital through pre-funded warrants and expand its equity incentive plan, these actions introduce significant dilution (24% overhang) and are reactive measures to underlying solvency issues. The high weighted average exercise price of existing options further suggests that current equity incentives are largely ineffective. A seasoned investor would recognize these fundamental issues as indicative of a company in deep distress with a high probability of further value erosion.

Keywords

Predictive Oncology, SEC Filing, DEF 14A, Proxy Statement, Annual Meeting, Corporate Governance, Executive Compensation, Equity Incentive Plan, Stock Options, Pre-Funded Warrants, Share Dilution, Going Concern, Internal Controls, Financial Reporting, Nasdaq Listing Rule, Biotechnology, Oncology, Digital Assets, Cryptocurrency